Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Blackledge

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
European Urology|January 1, 1996
Clinical progress with a new antiandrogen, Casodex (bicalutamide)G R Blackledge
Urology|January 1, 1996
High-dose bicalutamide monotherapy for the treatment of prostate cancerG R Blackledge
Zentralblatt Fur Gynakologie|December 13, 2005
Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical companyG R Blackledge
The Prostate. Supplement|January 1, 1994
Role of prostate-specific antigen as a predictor of outcome in prostate cancerG R Blackledge, K Lowery
Urology|January 1, 1996
Worldwide activity and safety of bicalutamide: a summary reviewG J Kolvenbag, G R Blackledge
Annals of the Royal College of Surgeons of England|September 1, 1986
Haemorrhage and perforation of gastrointestinal neoplasms during chemotherapyJ Randall, M L Obeid, G R Blackledge
European Urology|January 1, 1997
Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancerG R Blackledge, I D Cockshott, B J Furr
The Prostate|January 15, 1998
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical developmentG J Kolvenbag, G R Blackledge, K Gotting-Smith
British Journal of Urology|December 1, 1987
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancerL A Emtage, P W Lewis, G R Blackledge
European Journal of Cancer & Clinical Oncology|September 1, 1986
Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatmentG R Blackledge, T Latief, J J Mould, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
European Urology|January 1, 1996
Clinical progress with a new antiandrogen, Casodex (bicalutamide)G R Blackledge
Urology|January 1, 1996
High-dose bicalutamide monotherapy for the treatment of prostate cancerG R Blackledge
Zentralblatt Fur Gynakologie|December 13, 2005
Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical companyG R Blackledge
The Prostate. Supplement|January 1, 1994
Role of prostate-specific antigen as a predictor of outcome in prostate cancerG R Blackledge, K Lowery
Urology|January 1, 1996
Worldwide activity and safety of bicalutamide: a summary reviewG J Kolvenbag, G R Blackledge
Annals of the Royal College of Surgeons of England|September 1, 1986
Haemorrhage and perforation of gastrointestinal neoplasms during chemotherapyJ Randall, M L Obeid, G R Blackledge
European Urology|January 1, 1997
Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancerG R Blackledge, I D Cockshott, B J Furr
The Prostate|January 15, 1998
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical developmentG J Kolvenbag, G R Blackledge, K Gotting-Smith
British Journal of Urology|December 1, 1987
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancerL A Emtage, P W Lewis, G R Blackledge
European Journal of Cancer & Clinical Oncology|September 1, 1986
Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatmentG R Blackledge, T Latief, J J Mould, et al.
Pageof 5